A
Agnès Represa
Publications - 7
Citations - 586
Agnès Represa is an academic researcher. The author has contributed to research in topics: Antibody & Inflammation. The author has an hindex of 3, co-authored 6 publications receiving 283 citations.
Papers
More filters
Journal ArticleDOI
Association of COVID-19 inflammation with activation of the C5a-C5aR1 axis.
Julien Carvelli,Olivier Demaria,Frédéric Vély,Luciana Batista,Nassima Chouaki Benmansour,Joanna Fares,Sabrina Carpentier,Marie-Laure Thibult,Ariane Morel,Romain Remark,Pascale Andre,Agnès Represa,Christelle Piperoglou,Pierre Yves Cordier,Erwan Le Dault,Christophe Guervilly,Pierre Simeone,Marc Gainnier,Yannis Morel,Mikael Ebbo,Nicolas Schleinitz,Eric Vivier +21 more
TL;DR: Results suggest that blockade of the C5a–C5aR1 axis could be used to limit the infiltration of myeloid cells in damaged organs and prevent the excessive lung inflammation and endothelialitis that are associated with acute respiratory distress syndrome in patients with COVID-19.
Journal ArticleDOI
483 Association of COVID-19 inflammation with activation of the C5a-C5aR1 axis
Olivier Demaria,Julien Carvelli,Nassima Chouaki Benmansour,Joanna Fares,Luciana Batista,Marie-Laure Thibult,Ariane Morel,Sabrina Carpentier,Romain Remark,Agnès Represa,Frédéric Vély,Mikael Ebbo,Nicolas Schleinitz,Robert Zerbib,Yannis Morel,Eric Vivier +15 more
TL;DR: These results support the evaluation of avdoralimab to block C5a-C5aR1 axis as a mean of limiting myeloid cell infiltration in damaged organs and preventing the excessive lung inflammation and endothelialitis associated with ARDS in COVID-19 patients.
Journal ArticleDOI
Site-Specific Conjugation of Monomethyl Auristatin E to Anti-CD30 Antibodies Improves Their Pharmacokinetics and Therapeutic Index in Rodent Models.
Florence Lhospice,Delphine Bregeon,Christian Belmant,Patrick Dennler,Aristeidis Chiotellis,Eliane Fischer,Laurent Gauthier,Angelique Boedec,H. Rispaud,S. Savard-Chambard,Agnès Represa,N. Schneider,C. Paturel,M. Sapet,C. Delcambre,S. Ingoure,N. Viaud,C. Bonnafous,Roger Schibli,Roger Schibli,François Romagné +20 more
TL;DR: The in vitro and in vivo characterization of four novel ADCs that are based on the anti-CD30 antibody cAC10, which has the same polypeptide backbone as ADCETRIS, suggest that homogeneous ADCs display improved pharmacokinetics and better therapeutic indexes compared to those of chemically modified ADCs with variable DARs.
Journal ArticleDOI
Antitumor immunity induced by antibody-based natural killer cell engager therapeutics armed with not-alpha IL-2 variant
Olivier Demaria,Laurent Gauthier,Marie Vétizou,Audrey Blanchard Alvarez,Constance Vagne,Guillaume Habif,Luciana Batista,William Baron,Nourhène Belaïd,Mathilde J. H. Girard-Madoux,Cédric Cesari,Mélody Caratini,Frédéric Bosco,Olivier Benac,Julie Lopez,Aurore Fenis,Justine Galluso,Sylvia Trichard,Barbara Carrette,Florent Carrette,Aurélie Maguer,Solène Jaubert,A. Caceres Sansaloni,Robin Letay-Drouet,Camille Kosthowa,Naouel Lovera,Arnaud Dujardin,Fabien Chanuc,Mélanie Le Van,Sivan M. Bokobza,Nicolas Jarmuzynski,Camille Fos,Nicolas Gourdin,Romain Remark,Eric Lechevallier,N. Fakhry,Sébastien Salas,Jean-Laurent Deville,Roger Le Grand,Cécile Bonnafous,Lukas Vollmy,Agnès Represa,Sabrina Carpentier,Benjamin Rossi,Ariane Morel,Stéphanie Cornen,Ivan Perrot,Yannis Morel,Eric Vivier +48 more
TL;DR: In this paper , the design of tetraspecific molecules engaging natural killer (NK) cell-activating receptors NKp46 and CD16a, the β-chain of the interleukin-2 receptor (IL-2R), and a tumor-associated antigen (TAA) was reported.
Identification of immune checkpoints in COVID-19
Julien Carvelli,Olivier Demaria,Frédéric Vély,Luciana Batista,Nassima Chouaki Benmansour,Joanna Fares,Sabrina Carpentier,Marie-Laure Thibult,Ariane Morel,Pascale Andre,Agnès Represa,Christelle Piperoglou,Pierre Yves Cordier,Erwan Le Dault,Christophe Guervilly,Pierre Simeone,Marc Gainnier,Yannis Morel,Mikael Ebbo,Nicolas Schleinitz,Eric Vivier +20 more